TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Treatment of Insomnia in Palliative Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically verified malignant disease~2. Presence of metastatic / disseminated disease~3. Presence of insomnia syndrome defined as:~   1. Self-reported difficulty with initiating sleep (greater than 30 minutes to sleep onset) and/or difficulty maintaining sleep (greater than 30 minutes nocturnal waking time); and~  2. Sleep difficulty at least 3 nights per week; and~  3. Sleep difficulty that causes significant impairment of daytime functioning (The patient will be asked if sleep difficulty result in altered daytime function i.e. feeling tired, lack of energy)~4. Able to comply with all study procedures~5. Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.~Exclusion Criteria:~1. On-going treatment or previous treatment (within last 4 weeks) for more than consecutive 3 days with medications given for insomnia~2. Adverse reactions to zopiclone~3. History of substance abuse~4. Concomitant use of rifampicin and erythromycin~5. Any other contraindication listed on the summary of product characteristics of the investigated medicinal product:~   1. Myasthenia gravis~  2. An established diagnosis of Severe impairment of respiratory function~  3. An established diagnosis of Severe hepatic insufficiency.(Child-Pugh grade B or C)~  4. An established diagnosis of sleep apnea~  5. Known hypersensitivity to the drug or to any component in its formulation: Lactose monohydrate, Calcium hydrogen phosphate, Maize starch, Croscarmellose sodium, Magnesium stearate, Titanium dioxide (E 171), Hypromellose, Iron oxide yellow/Iron oxide red (E 172) and Macrogol~6. Unfit for participation for any reason as judged by the investigator~7. Pregnancy or lactation~8. Women of reproductive age not willing or unable to employ an effective method of contraception (sterilization, using IUD or oral contraception)~9. Scheduled surgery within the next week~10. In the need of change in scheduled opioid dose at baseline (study visit 1)~11. Scheduled intravenous administration of chemotherapy during the study period (from baseline to day 8) or intravenous administration of chemotherapy during the last week~12. Change in corticosteroid dose last week before baseline or planned dose change in corticosteroid dose within 7 days from baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zopiclone (Type: ACTIVE_COMPARATOR): Zopiclone six nights
- Placebo (Type: PLACEBO_COMPARATOR): Placebo six nights

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* absence of evidence of any active or chronic disease;~* Free of clinical significant systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of Adverse Events;~* Have at least 2 (non-subungual) common warts or at least 2 plantar warts on non-genital, nonfacial skin~Exclusion Criteria:~* Any clinically significant abnormality that in the opinion of the investigator would interfere with the study objectives or compromise subject safety;~* For women: a positive pregnancy test and/or nursing at screening or women who plan to become pregnant or are breastfeeding;~* A positive test for drugs of abuse at screening;~* History of alcohol or illicit drug abuse (alcohol abuse defined as alcohol consumption \> 28 units/week);~* Positive test results for Hepatitis B, Hepatitis C or HIV;~* Have used salicylic acid or any other over-the-counter wart-removing product in the treatment area within 30 days prior to starting the study or cryotherapy within 60 days of starting the study;~* Have required systemic intake of immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 30 days prior to enrollment or during the course of the study. Routine use of inhaled or intranasal corticosteroids during the study is allowed;~* Have a known sensitivity to any of the investigational product ingredients~* Clinically relevant abnormal laboratory results, ECG, vital signs, or physical findings at screening;~* Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times in the past year;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- CLS003 (Type: EXPERIMENTAL): Topical digoxin/furosemide
- Digoxin topical formulation (Type: EXPERIMENTAL): None
- Furosemide topical formulation (Type: EXPERIMENTAL): None
- Vehicle topical formulation (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2008; postbronchodilator FEV1/FVC \< 70%, and postbronchodilator FEV1 ≥ 30% and \< 80% predicted~* Current or former cigarette smokers~Exclusion Criteria:~* Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit~* Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1~* Patient with any clinically significant respiratory conditions other than COPD, cardiovascular conditions or mental illness~* History or presence of asthma verified from medical records~* Chronic use of oxygen therapy greater than or equal to 15 hours per day~* Patient with uncontrolled infection due to HIV and/or active hepatitis~* Patients with a history of hypersensitivity reaction to inhaled anticholinergics~* Patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks
- 2 (Type: EXPERIMENTAL): Aclidinium bromide 400 μg dose twice per day, inhaled for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg will continue to receive open label 400µg aclidinium bromide for 40 weeks
- 3 (Type: PLACEBO_COMPARATOR): Dose-match placebo, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on placebo will receive open label 400µg aclidinium bromide for 40 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Rich Plasma Injection for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* stage 1-2-3 symptomatic OA patients according to Kellgren / Lawrence staging~* mean VAS pain score of \>4 of 10 (worst possible pain) over the course of 7 days during the previous month~Exclusion Criteria:~* OA secondary to joint inflammatory diseases,~* generalized OA,~* metabolic diseases of the bone,~* coexisting backache,~* the presence of hematological disease (coagulopathy),~* bilateral symptomatic lesions and advanced stages (grade 4) of OA,~* patients who had received intra-articular injections within 3 months or arthroscopic lavage in the previous 1 year,~* patients who were receiving immunosuppressive,~* patients with current use of anticoagulant medications,~* NSAIDs used in the 5 days before blood donation,~* major axis deviation (more than 15 degree of varus or more than 5 degree of valgus deviation),~* patients with a hemoglobin level less than 11.5 g/dL,~* platelets level less than 100,000/μL,~* associated comorbidities, infection, tumor, crystal arthropathies, anemia, tense joint effusion and pregnancy or possibility of pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PRP group (Type: EXPERIMENTAL): Intraarticular 5 ml single PRP injection
- Saline group (Type: PLACEBO_COMPARATOR): Intraarticular 5 ml single saline injection
- Multiple PRP group (Type: EXPERIMENTAL): Intraarticular 3 dose of 5 ml PRP injection (0, 1, 3 month injection)
- Multiple saline group (Type: PLACEBO_COMPARATOR): Intraarticular 3 dose of 5 ml saline injection (0, 1, 3 month injection)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Ketamine for Acute Traumatic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients aged 18-70 years, with mild to moderate blunt trauma (sustained in road, workplace and home accidents) causing moderate to severe pain (≥ 80mm score on a 100mm Visual Analog Scale=VAS) were eligible for participation in the study. Inclusion criteria also included a Glasgow Coma Score (GCS) of 15, body weight of 50-110 kg, systolic blood pressure of 90-160 mmHg, heart rate \<100 bpm. Patients were also required to have an American Society of Anesthesiologists (ASA) score of 1 or 2, deny head injury, and deny regular use or use of opiates.~Exclusion Criteria:~Any analgesia received within the prior 3 hours, allergic sensitivity to morphine or ketamine, a large meal ingested within the previous hour, pregnancy, deviated nasal septum or trauma to the nose, and a history of a psychiatric condition. Despite evidence that ketamine does not exacerbate intracranial hemorrhage in patients with head trauma, patients with head injury complaining of loss of consciousness, dizziness, vomiting, or nausea were excluded as well.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IN Ketamine (Type: EXPERIMENTAL): A single administration of 1 mg/kg ketamine hydrochloride delivered in an intranasal route using an atomizer
- IM Morphine (Type: ACTIVE_COMPARATOR): A single administration of 0.15 mg/kg intramuscular morphine
- IV Morphine (Type: ACTIVE_COMPARATOR): A single administration of 0.1 mg/kg slow intravascular bolus of morphine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed active head lice infestation~Exclusion Criteria:~* Allergy to pediculicides or hair care products~* Scalp conditions other than head lice~* Previous head lice treatment within the past 4 weeks~* Current antibiotic treatment

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Malathion Gel (Type: EXPERIMENTAL): Malathion gel 0.5% 30 minute application
- Nix Crème Rinse (Type: ACTIVE_COMPARATOR): Nix Crème Rinse applied to scalp for 10 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Ocular Criteria~* RP, typical forms(i.e. elevated final dark adaptation threshold,retinal arteriolar narrowing,and reduced and delayed full-field ERGs).~* Best-corrected visual acuity 20/100 or better~* HFA program 30-2 total point score \>= 250 decibels(dB)to a size V white test light~* No confounding ocular disease such as glaucoma,uveitis,diabetic retinopathy,posterior subcapsular cataract more than 11% of total lens area (ie equivalent to P3 on Lens Opacity Classification System III)and pupil diameter after dilation less than 6 mm.~Dietary Criteria~* Fruit and vegetable intake \< 10 servings/d~* Spinach or kale intake \< 1 serving/d, i.e. \<1/2 cup of cooked spinach or kale per day~* Dietary lutein intake \<=5.4 mg/d as estimated from food frequency questionnaire~* No intake of cod liver oil or omega-3 capsules~* Dietary preformed vitamin A intake \<= 10,000 IU/d~* Supplement intake \<= 5,000 IU/d of Vitamin A and \<= 30 IU/d of Vitamin E~* Consumption \<= 3 alcoholic beverages/d~Medical and other criteria~* Age 18-60 y~* Body mass index \< 40 and weight \>= 5th percentile for age,gender,and height~* Serum retinol level \<= 100 micrograms/deciliter and serum retinyl ester level \<= 380 nanomoles/Liter~* Serum cholesterol \< 300 micrograms/deciliter and serum triglyceride level \<400 micrograms/deciliter~* No clinically significant abnormality on blood cell count, glucose level, blood urea nitrogen level, serum lipid panel results or serum liver function profile.~* Not pregnant or planning to become pregnant~* Not smoking currently~* Agreed not to know tablet content or course of condition until the end of the trial.~* No other disease which might affect absorption or metabolism of lutein or vitamin A.~* Only one patient per family was accepted into the study.~Exclusion Criteria:~* Women who are pregnant or planning to become pregnant (Vitamin A supplements can increase the risk of birth defects.)~* Current participation in another clinical trial for RP~* Patients with atypical forms such as paravenous RP, pericentral RP, sector RP,unilateral RP,Refsum disease, Bardet-Biedl syndrome, retinitis punctata albescens and cone-rod dystrophy were excluded as were patients with RP and profound congenital deafness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lutein plus 15,000 IU/d Vitamin A (Type: EXPERIMENTAL): Daily intake of 12mg of Lutein plus 15,000 IU/d of Vitamin A palmitate
- Control plus 15,000 IU/d Vitamin A (Type: PLACEBO_COMPARATOR): Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Probiotics in Adults With Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Otherwise well and meet the criteria for IBS as defined by the Rome III criteria~* Ability to speak and understand English~* Telephone access~* IBS Severity Scale score of \>= 75~Exclusion Criteria:~* Organic disease accounting for GI symptoms.~* Chronic illness such as renal disease, congenital heart disease, diabetes, moderate or severe asthma, abdominal surgery, or immunosuppressed (e.g., organ transplant recipient).~* Have received extraneous probiotic (i.e., not in a food such as yogurt) within 4 months of starting the study.~* Subjects who are taking prescription or over-the-counter medications for GI disorders that completely relieve their symptoms because by definition these individuals do not have IBS (e.g., antacids, proton pump inhibitors, histamine receptor antagonists).~* Medication allergies or contraindications which would preclude antimicrobial treatment for potential infection with VSL#3 component organisms.~* Pregnancy.~* Subjects who have an individual in the household who is immunosuppressed (e.g., genetic immune disorder, organ transplant).~* Oral temperature \> 38.0 degrees Celsius.~* Poorly controlled hypertension, history of cardiac disease, stroke/cerebral vascular accident, bowel ischemia, or other risk factors for bowel ischemia.~* History of acute or chronic pancreatitis~* Cardiac valvular disease or other risk factor for endocarditis~* Subjects who indicate on the IBS scoring questionnaire that their pain is severe or very severe.~* Subjects who pain lasts more than 5 out of 10 days.~* Subjects whose scores indicate more than mild IBS who are over 45 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Probiotic (Type: EXPERIMENTAL): To determine the safety and effectiveness of the probiotic VSL#3 in adults with irritable bowel syndrome (IBS).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Artesunate Study in Severe Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female children aged 6 months and ≥ 5kg to 10 years, inclusive.~* Clinical diagnosis of severe P. falciparum malaria (see Appendix B) requiring hospitalization.~* Parasitemia (more than 5,000 parasites/microL on initial blood smear).~* Availability of child's parent/guardian and their willingness to provide written informed consent in accordance to local practice.~* Willingness and ability to comply with the study protocol for the duration of the study.~* Willingness to remain in the hospital for 4 days~Exclusion Criteria:~* Known serious adverse reaction or hypersensitivity to artemisinins, including artesunate, artemether, dihydroartemisinins or Co-Artem (artemether/lumefantrine).~* Any underlying disease that may compromise the diagnosis and the evaluation of the response to the study medication (including concomitant infection, concomitant neurological disease and malnutrition)~* Participation in any investigational drug study during the 30 days prior to Screening.~* Adequate anti-malarial treatment within 24 hours prior to admission.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- cohort 1 (Type: ACTIVE_COMPARATOR): 2.4 mg/kg iv artesunate at 0, 12, 24, 48and 72 hours
- cohort 2 (Type: EXPERIMENTAL): 4.0 mg/kg iv Artesunate at 0, 24 and 48 h

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Physiological Flow of Liquids Used in Dysphagia Management (Neuro)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults (18+) with a confirmed diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Parkinson's disease (PD)~Exclusion Criteria:~* People with a prior medical history of stroke~* People with a prior medical history of acquired brain injury~* People with a prior medical history of spinal or spinal cord injury~* People with a prior medical history of cancer or surgery in the head and neck region~* People who have had radiation to the head and neck for cancer~* People who have a prior history of swallowing problems (e.g., from childhood, medical complication)~* People with significant breathing difficulties (e.g., rely on mechanical ventilation)~* People who rely solely on tube-feeding for all meals and nutrition~* People who have Type I (insulin-dependent) Diabetes~* Women who are pregnant~* People who have allergies to barium, potato starch, corn starch, xanthan gum, milk products, latex or dental glue

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Amyotrophic Lateral Sclerosis (Type: None): We will be recruiting individuals with confirmed or probably ALS, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
- Parkinson's Disease (Type: None): We will be recruiting individuals with a diagnosis of Parkinson's disease, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete